Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAF312 crossover study in neurogenic detrusor overactivity due to spinal cord lesions
2010-021137-32Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SAF312 in detrusor hyperreflexia (DH) and overactive bladder (OAB) (2 arms), sponsored by Novartis. Primary endpoint: Change in maximum cystometric capacity. Started Oct 2010; status: terminated.
02
Drugs
SAF312
03
Conditions
detrusor hyperreflexia (DH)overactive bladder (OAB)
Beyond the preview
Go deeper on 2010-021137-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021137-32.